Unknown

Dataset Information

0

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.


ABSTRACT: The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in this setting. The study was designed as multicenter, randomized phase II trial, preceded by a lead-in safety phase. The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily). Overall, 28 patients were screened, and 26 patients were enrolled. Five dose levels were explored. DLTs, mainly myelosuppression, occurred in 10 patients. Grade 3 or 4 neutropenia was recorded in 7 patients (26.9%) and thrombocytopenia in 11 patients (42.3%). No significant effect of CCNU coadministration on dasatinib pharmacokinetics was found. Median progression-free survival (PFS) was 1.35 months (95% confidence interval: 1.2-1.4) and 6-month PFS was 7.7%. In this phase I study of recurrent glioblastoma patients, the combination of CCNU and dasatinib showed significant hematological toxicities and led to suboptimal exposure to both agents.

SUBMITTER: Franceschi E 

PROVIDER: S-EPMC3499012 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

Franceschi Enrico E   Stupp Roger R   van den Bent Martin J MJ   van Herpen Carla C   Laigle Donadey Florence F   Gorlia Thierry T   Hegi Monika M   Lhermitte Benoit B   Strauss Lewis C LC   Allgeier Anouk A   Lacombe Denis D   Brandes Alba A AA  

Neuro-oncology 20121022 12


The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in this setting. The study was designed as multicenter, randomized phase II trial, preceded by a lead-in safety phase. The safety component reported here, which also investigated pharmacokine  ...[more]

Similar Datasets

| S-EPMC5762006 | biostudies-literature
| S-EPMC5514626 | biostudies-literature
| S-EPMC2667826 | biostudies-literature
| S-EPMC8557653 | biostudies-literature
| S-EPMC7919338 | biostudies-literature
| S-EPMC7493746 | biostudies-literature
| S-EPMC3869574 | biostudies-literature
| S-EPMC4483124 | biostudies-literature
| S-EPMC11303865 | biostudies-literature
| S-EPMC6788934 | biostudies-literature